5/11/21 FDA gave IND approval for a BRD9 protein degrader

Since late 2018 we have been waiting for the development of this. Two companies, C4 therapeutics, and Foghorn Therapeutics have been developing treatments. Now Foghorn has received approval for a phase 1/2 IND trial for this BRD9 approval. This treatment is specifically developed for synovial sarcoma. Has any one enrolled in this clinical trial? Any information from doctors?
Here is the announcement: * Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma

Hope this is one breakthrough.

1 Like